Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018165532) METHODS FOR DIAGNOSING AND TREATING GASTRIC CANCER USING MIRNA EXPRESSION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/165532 International Application No.: PCT/US2018/021713
Publication Date: 13.09.2018 International Filing Date: 09.03.2018
IPC:
A61B 5/145 (2006.01) ,A61K 39/00 (2006.01) ,A61N 5/10 (2006.01) ,C12Q 1/68 (2018.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
B
DIAGNOSIS; SURGERY; IDENTIFICATION
5
Measuring for diagnostic purposes; Identification of persons
145
Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
N
ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
5
Radiation therapy
10
X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
Applicants:
BAYLOR RESEARCH INSTITUTE [US/US]; 3310 Live Oak Street Suite 501 Dallas, TX 75204, US
Inventors:
GOEL, Ajay; US
IZUMI, Daisuke; US
Agent:
SHISHIMA, Gina, N.; US
Priority Data:
62/469,85710.03.2017US
Title (EN) METHODS FOR DIAGNOSING AND TREATING GASTRIC CANCER USING MIRNA EXPRESSION
(FR) PROCÉDÉS DE DIAGNOSTIC ET DE TRAITEMENT DU CANCER GASTRIQUE AU MOYEN D'EXPRESSION DE MIARN
Abstract:
(EN) Dysregulated expression of microRNAs (miRNAs) has emerged as a hallmark feature in human cancers. Aspects of the disclosure relate to methods for selecting optimal therapy for a patient from several alternative treatment options. A major clinical challenge in cancer treatment is to identify the subset of patients who will benefit from a therapeutic regimen, both in metastatic and adjuvant settings. The number of anti-cancer drugs and multi-drug combinations has increased substantially in the past decade, however, treatments continue to be applied empirically using a trial-and-error approach. Here methods and compositions are provided to determine the optimal treatment option for gastric cancer patients.
(FR) L'expression dérégulée de micro-ARN (miARN) a émergé en tant que caractéristique de marquage dans les cancers humains. Des aspects de l'invention concernent des procédés de sélection d'une thérapie optimale pour un patient à partir de plusieurs options de traitement alternatives. Un défi clinique majeur dans le traitement du cancer est d'identifier le sous-ensemble de patients qui bénéficieront d'un régime thérapeutique, à la fois dans des réglages métastasiques et d'adjuvants. Le nombre de médicaments anticancéreux et de combinaisons de médicaments multiples a augmenté sensiblement dans la dernière décennie, cependant, des traitements continuent d'être appliqués de manière empirique à l'aide d'une approche par essai et erreur. L'invention concerne des procédés et des compositions pour déterminer l'option de traitement optimale pour des patients atteints d'un cancer gastrique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)